[Anti-HBs-F(ab)'2 to the seroconversion of HBsAg carriers].
The exogenous anti-HBs-F(ab)'2 was given to the HBsAg carriers for the study of its effect of seroconversion in vivo. 30 HBsAg carriers, with a duration of 2-15 years (HBeAg positive 18 and anti-HBe positive 12) were studied after intramuscular infection of anti-HBs-F(ab)'2. In the HBeAg group, the cut off value of HBeAg decreased significantly (P < 0.01) in 18 carriers, of which 6 seroconversed to anti-HBe, all the HBe-Ag carriers had a high S/N ratio of anti-HBs-anti-Id (RIA) but after 12-week treatment the ratio decreased significantly (P < 0.01). Six of 18 HBV DNA positive carriers conversed to negative (33%) and 8 of 13 DNA-P positive conversed to negative (61%). 12 anti-HBe positive carriers showed no seroconversion.